Early access
Sign in
Taking people in SwitzerlandPhase 4

Pausing beta-blockers around heart valve replacement for aortic stenosis

Tests stopping beta-blocker medicine for a while in people having aortic valve replacement.

Key facts

Who runs it
University Hospital, Basel, Switzerland
Where
Basel, Bern, Geneva, and Zurich, SwitzerlandSee the 4 sitesAlso in 2 other countries, 7 sites
Registry title
Impact of Beta-blocker on Outcome Among Patients Undergoing Transcatheter Aortic Valve Replacement (B-TAVR)
Status
Recruiting
Phase
Phase 4
People taking part
498 people, planned
Started
4 Jul 2024
Expected to end
May 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Transcatheter aortic valve replacement in the absence of B-blocker treatment
  • Transcatheter aortic valve replacement
Record updated
28 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with severe aortic stenosis who take a beta-blocker and have a planned TAVR (valve replacement through a catheter). It tests pausing the beta-blocker around the procedure.

Age
Over 18 years
Sex
All sexes
Disease stage
Severe aortic stenosis (narrowed heart valve) that causes symptoms. TAVR must be planned in advance, not urgent.
Earlier treatment
Must have a reason to take a beta-blocker and have taken it for at least 1 month before joining.

Main reasons for not taking part

  • Emergency or urgent need for TAVR
  • Unstable blood circulation needing drugs to support the heart
  • Already has a permanent pacemaker or needs one
  • Earlier bad reaction to beta-blockers
  • Life expectancy under 1 year, or pregnant or breastfeeding

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Informed Consent must be signed by the subject prior to any study intervention
  • Adult patients (> 18 years) with severe symptomatic aortic stenosis eligible and scheduled for elective TAVR and are able to give consentand are able to give consent
  • Indication for B-blocker therapy with a prior treatment duration of at least 1 month before inclusion

Who cannot take part

  • Hemodynamically unstable patients receiving inotropic medication
  • Prior permanent pacemaker implantation
  • Prior intolerance of B-blocker medication
  • Known or suspected non-compliance, drug, or alcohol abuse
  • Participation in another study with investigational drug within the 30 days preceding and during the present study
  • Previous enrolment into the current study
  • Inability to give consent, or follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
  • Emergency or urgent indication for TAVR
  • Existing indication for pacemaker implantation
  • Hemodynamic relevant left ventricular outflow tract obstruction
  • Life expectancy < 1 year
  • Being in a dependent relationship with the trial site
  • Pregnancy or breast feeding women

Where in Switzerland

Also in 2 other countries, 7 sites

  • University Hospital BaselBasel, SwitzerlandContact: Nicole Gilgen, Dr. med.Taking people
  • Inselspital, Bern University HospitalBern, SwitzerlandContact: Thomas Pilgrim, Prof. Dr.Taking people
  • Geneva University HospitalsGeneva, SwitzerlandContact: Stéphane Noble, Prof. Dr.Taking people
  • University Hospital of ZurichZurich, SwitzerlandContact: Albert Markus Kasel, Prof. Dr.Taking people

About the trial

What the trial wants to find out

This is a multi-centric, open-label, randomized trial to evaluate the safety and efficacy of temporary discontinuation of beta-blocker treatment in patients undergoing transcatheter aortic valve replacement.

The 2 groups in the trial

  • Pausing groupTreatment being tested

    Subjects in the pausing group will stop their B-blocker medication 72h before the scheduled transcatheter aortic valve replacement (TAVR) procedure. Post-procedural B-blocker therapy will be resumed 72h after the procedure using the same type and dosage as prescribed before.

    Treatment: Transcatheter aortic valve replacement in the absence of B-blocker treatment

  • Control groupOther group

    Subjects in the control group will keep their B-blocker medication in their prescribed dose during the scheduled TAVR procedure.

    Treatment: Transcatheter aortic valve replacement

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
Impact of Beta-blocker Administration on Outcome Among Patients Undergoing Transcatheter Aortic Valve Replacement B-TAVR
Plain-language title
Pausing beta-blockers around heart valve replacement for aortic stenosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
28 November 2025